South Africa has launched the rollout of Lenacapavir, a long-acting injectable drug designed to prevent HIV infection [1].

This deployment represents a shift in prevention strategies by reducing the frequency of medication. Because the drug requires fewer doses than daily pills, it may increase adherence and accessibility for high-risk populations in regions with significant health burdens.

The rollout event took place at the Lilian Ngoyi Stadium in Secunda, Mpumalanga [2]. The announcement coincided with the International AIDS Conference held in Rio de Janeiro, Brazil, where global leaders and the international HIV community gathered to discuss sustainable funding and prevention strategies [1, 2].

Lenacapavir is administered two times per year [3]. This schedule is a departure from traditional preventative treatments that require daily adherence to remain effective. The drug's efficacy is supported by two landmark clinical trials that demonstrated strong protection against HIV infection [4].

South African health officials are utilizing the drug to address the nation's high HIV burden [1, 2]. While South Africa has officially launched the rollout, some reports indicate Eswatini may have been the first African country to receive the shot [5, 2].

Global health leaders at the Rio conference used the South African example to highlight the potential of long-acting technology. The focus remains on how to scale these innovations to ensure that the most vulnerable populations have access to the latest medical advancements [1].

“Lenacapavir is administered twice yearly”

The transition from daily oral PrEP to a twice-yearly injection addresses the primary barrier to HIV prevention: human adherence. By reducing the dosing schedule from 365 days to two instances per year, health officials can potentially lower infection rates in high-burden areas where pharmacy access or social stigma makes daily pill-taking difficult.